Delphia Therapeutics

D3 Bio

This biotechnology company develops precision medicines and oncology therapeutics for patients with cancer and immunological conditions.

Meliora Therapeutics

This company develops a machine-learning platform to identify drug mechanisms and create precision oncology treatments for pharmaceutical partners and cancer patients.

Celleron Therapeutics

This biopharmaceutical company develops precision medicine drugs and companion diagnostics for cancer patients to provide personalised oncology treatments.

Tango Therapeutics

This biotechnology company develops precision oncology medicines targeting genetic vulnerabilities in cancer cells for patients with solid tumours.

Haptena Therapeutics

This biotechnology company develops immunotherapies for patients with oncogene-driven cancers by integrating precision oncology with immune engineering.

Aprea Therapeutics

This company develops targeted cancer therapies for patients with biomarker-defined tumours and DNA damage response pathway defects.

MyCural Therapeutics

This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.